echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > STROKE: Fatty liver may increase the risk of stroke

    STROKE: Fatty liver may increase the risk of stroke

    • Last Update: 2021-01-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Non-alcoholic fatty liver disease (NAFLD), commonly known as fatty liver disease, is the most common chronic liver disease, affecting about 25 percent of adults.
    many middle-age and even young people may have been warned of "mild fatty liver" on their medical reports, but they were considered "irrelevant" and not taken seriously.
    And in November, researchers at Karolinska College in Sweden and Massachusetts General Hospital in the United States, after studying 51 years of cohort study data in Sweden, reported that even mild fatty liver disease increased the risk of death by 71 percent, and that the risk was directly related to the severity of fatty liver disease.
    , fatty liver disease is often associated with obesity, diabetes and even an increased risk of diseases both inside and outside the liver.
    fatty liver can also increase the risk of cardiovascular disease.
    , will fatty liver increase the risk of stroke? To this end, a team of professors from Beijing Tiantan Hospital, Professor Wang Congjun, studied the problem.
    results were published in the latest issue of stroke.
    the study is part of the Kaifeng study, a forward-looking cohort study that investigates risk factors for noncommunicable diseases only.
    excluding alcoholism and other liver diseases, the researchers included participants with no history of stroke, cancer or myocardial infarction.
    NAFLD is evaluated with an ultrasound.
    with NAFLD were further strated into mild, moderate and severe groups.
    major findings are the first of its time in a stroke event.
    results include myocardial infarction and combined cardiovascular events.
    use the Cox proportional risk model to estimate the risk ratio of stroke events and 95% CI based on the presence and severity of NAFLD.
    Also adjusted for age, gender, physical activity, body mass index, smoking, history of hypertension, diabetes, hypercholesterolemia, lipid-lowering drugs, HDL (high density lipoprotein), triglycerides, hsCRP (hypersensitive C reaction protein) and peri-abdominal blood sugar.
    the study, which was conducted over a 10.34-year period, involved 3,490 strokes in 79,905 participants and 24,874 (31.18%) in NAFLD.
    were 16 percent more likely to have ischemic stroke in NAFLD patients after adjusting for mixed variables than participants who did not have NAFLD at baseline.
    further analysis found that the risk ratios for mild, moderate and severe NAFLD patients were 1.15, 1.19 and 1.21, respectively.
    stroke and heart attack during follow-up.
    , with the social and economic development and the improvement of people's living standards, the incidence of fatty liver disease in China has risen sharply in recent years.
    In 2019, a meta-analysis published in the journal Hepatology by Professor Li Hongliang, a former dean of Wuhan University's School of Basic Medicine, showed that in the past 10 years, the number of fatty liver patients in China has jumped from 18% to 29.2%, especially among middle-age people, men, the Northwest Territories, Taiwan, areas with a per capita GDP greater than 100,000 yuan, and Uighurs and Huis.
    , "fatty liver" may seem flat, but it increases the risk of a variety of diseases, including stroke, in the future.
    , it is important to raise public awareness of fatty liver disease and intervene in a timely manner.
    : Xu J, et al. Severity of Nonalcoholic Fatty Liver Disease and Risk of Future Ischemic Stroke Events. Stroke. 2021 Jan; 52(1):103-110. doi: 10.1161/STROKEAHA.120.030433.MedSci Original Source: MedSci Original Copyright Notice: All notes on this website "Source: Met Medical" or "Source: MedSci Original" text, images and audio and video materials, copyrights are owned by Metz Medicine, without authorization, no media, website or individual may reproduce, authorized to reproduce with the words "Source: Mets Medicine".
    all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
    at the same time reproduced content does not represent the position of this site.
    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.